Trial · NCT00004978
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| New or Recurrent HIV Disease Progression Event Including Death | rIL-2 | 159 | participants | ||
| New or Recurrent HIV Disease Progression Event Including Death | No rIL-2 | 165 | participants | ||
| New or Recurrent Serious HIV Disease Progression Event Including Death | rIL-2 | 126 | participants | ||
| New or Recurrent Serious HIV Disease Progression Event Including Death | No rIL-2 | 130 | participants | ||
| Number of Participants Who Died From Any Cause | rIL-2 | 107 | participants | ||
| Number of Participants Who Died From Any Cause | No rIL-2 | 116 | participants | ||
| Participants With a New Disease Progression Event or Death | rIL-2 | 154 | participants | ||
| Participants With a New Disease Progression Event or Death | No rIL-2 | 164 | participants | ||
| Absolute CD4 Cell Counts Averaged Throughout Followup | rIL-2 | 715.4 | Standard Deviation 273.1 | cells/mm^3 | |
| Absolute CD4 Cell Counts Averaged Throughout Followup | No rIL-2 | 556.3 | Standard Deviation 193.0 | cells/mm^3 | |
| Plasma HIV RNA Levels | rIL-2 | 2.20 | Standard Deviation 0.65 | log10 HIV-RNA | |
| Plasma HIV RNA Levels | No rIL-2 | 2.17 | Standard Deviation 0.61 | log10 HIV-RNA | |
| Number of Participants With Changes in Anti-retroviral Treatment (ART) | rIL-2 | 1760 | participants | ||
| Number of Participants With Changes in Anti-retroviral Treatment (ART) | No rIL-2 | 1751 | participants | ||
| Grade 4 Signs and Symptoms | rIL-2 | 466 | Participants | ||
| Grade 4 Signs and Symptoms | No rIL-2 | 383 | Participants | ||
| Pattern of Use of Prophylaxis for Opportunistic Infections | rIL-2 | 54 | participants | ||
| Pattern of Use of Prophylaxis for Opportunistic Infections | No rIL-2 | 53 | participants | ||
| Hepatic, Metabolic, and Cardiac Conditions | rIL-2 | 134 | participants | ||
| Hepatic, Metabolic, and Cardiac Conditions | No rIL-2 | 136 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00004978/results